Skip to main content
PHRPhreesia, Inc.Sell5.9·$10.24-1.06%

Phreesia (PHR) Q2 2026 earnings — TrendMatrix coverage

MISS-14.3% vs estimateEPS $0.28 vs $0.32 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.28
Estimate
$0.32
Surprise
-14.3%
Revenue (period 2026-07-31)
$129.5M
Score at report (before → after)
5.65.8/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Phreesia (PHR) missed the $0.32 estimate with diluted EPS of $0.28 — a large 14.3% shortfall. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 5.8/10 after the report — the engine's score rose despite the miss.

Around the report

Coverage in the report window

  • DA Davidson Maintains Buy on Phreesia, Lowers Price Target to $13benzinga, 2026-09-04
  • Baird Maintains Neutral on Phreesia, Raises Price Target to $11benzinga, 2026-09-04
  • Phreesia Files Shelf Prospectus For Offering; Size Not Disclosedbenzinga, 2026-09-03
Current read · as of 2026-09-17

Where TrendMatrix's rating stands now

TrendMatrix currently rates PHR Sell at 5.9/10.

1 of the last 4 quarters beat the estimate; this quarter's -14.3% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2026-12-07.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Attractive valuation

What argues against it

  • V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
  • Consecutive earnings misses (2)
  • Negative momentum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$10.24
Price target
$12.54
Stop
$9.72
Upside to target
+22.5%
Reward-to-risk
2.6:1

The stock trades at 57.5× trailing but 6.4× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 30 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare context

PHR at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Health Information Services
Market cap
$642.4M
P/E (fwd)
6.4
P/E (ttm)
57.5
52-week range
$7.77$25.00
Off 52-week high
59.0%
RSI (14)
30
Volume vs avg
0.74×
Score today
5.9/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks PHR Earnings Q2 2026 earnings